Neuroprotective Therapy for Parkinson's Disease
Identifieur interne : 002010 ( Main/Exploration ); précédent : 002009; suivant : 002011Neuroprotective Therapy for Parkinson's Disease
Auteurs : William C. KollerSource :
- Experimental Neurology [ 0014-4886 ] ; 1997.
Abstract
The concept of neuroprotection relates to the fact that intervention may be able to interfere with the pathogenesis of neuronal cell death. Neuroprotective therapy may make it possible to delay disease progression or prevent the disease altogether. The pathophysiological mechanism of cell death in Parkinson's disease is unknown; however, hypotheses have been developed. The discovery that the toxin MPTP can cause Parkinson's disease both in humans and in animals strengthened the hypothesis that either exogenous or endogenous toxins may be involved in the mechanism of cell death in Parkinson's disease. The mechanism of MPTP toxicity has been elucidated, lending several possible mechanisms for therapeutic intervention in Parkinson's disease. Current data suggest that oxidative stress may play a prominent role in the pathogenesis of Parkinson's disease. It is possible that the generation of free radicals leads to neuronal cell death. There is also evidence that mitochondrial damage may play a role in the pathogenesis of Parkinson's disease. Other theories of possible pathogenesis include excitotoxicity, disturbances of calcium homeostasis, immunological mechanisms, and infectious etiologies. The first agent to be tested as a candidate for neuroprotection was the MAO-B inhibitor deprenyl. Evidence is reviewed for and against the theory that this drug is neuroprotective.
Url:
DOI: 10.1006/exnr.1996.6383
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Neuroprotective Therapy for Parkinson's Disease</title><author><name sortKey="Koller, William C" sort="Koller, William C" uniqKey="Koller W" first="William C." last="Koller">William C. Koller</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:DAA9FBEF109DE88D77954D1FD46657BF3F56D338</idno><date when="1997" year="1997">1997</date><idno type="doi">10.1006/exnr.1996.6383</idno><idno type="url">https://api.istex.fr/document/DAA9FBEF109DE88D77954D1FD46657BF3F56D338/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">001B86</idno><idno type="wicri:Area/Main/Curation">001918</idno><idno type="wicri:Area/Main/Exploration">002010</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Neuroprotective Therapy for Parkinson's Disease</title><author><name sortKey="Koller, William C" sort="Koller, William C" uniqKey="Koller W" first="William C." last="Koller">William C. Koller</name><affiliation><wicri:noCountry code="subField">314</wicri:noCountry></affiliation></author></analytic><monogr></monogr><series><title level="j">Experimental Neurology</title><title level="j" type="abbrev">YEXNR</title><idno type="ISSN">0014-4886</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1997">1997</date><biblScope unit="volume">144</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="24">24</biblScope><biblScope unit="page" to="28">28</biblScope></imprint><idno type="ISSN">0014-4886</idno></series><idno type="istex">DAA9FBEF109DE88D77954D1FD46657BF3F56D338</idno><idno type="DOI">10.1006/exnr.1996.6383</idno><idno type="PII">S0014-4886(96)96383-9</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0014-4886</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The concept of neuroprotection relates to the fact that intervention may be able to interfere with the pathogenesis of neuronal cell death. Neuroprotective therapy may make it possible to delay disease progression or prevent the disease altogether. The pathophysiological mechanism of cell death in Parkinson's disease is unknown; however, hypotheses have been developed. The discovery that the toxin MPTP can cause Parkinson's disease both in humans and in animals strengthened the hypothesis that either exogenous or endogenous toxins may be involved in the mechanism of cell death in Parkinson's disease. The mechanism of MPTP toxicity has been elucidated, lending several possible mechanisms for therapeutic intervention in Parkinson's disease. Current data suggest that oxidative stress may play a prominent role in the pathogenesis of Parkinson's disease. It is possible that the generation of free radicals leads to neuronal cell death. There is also evidence that mitochondrial damage may play a role in the pathogenesis of Parkinson's disease. Other theories of possible pathogenesis include excitotoxicity, disturbances of calcium homeostasis, immunological mechanisms, and infectious etiologies. The first agent to be tested as a candidate for neuroprotection was the MAO-B inhibitor deprenyl. Evidence is reviewed for and against the theory that this drug is neuroprotective.</div></front></TEI><affiliations><list></list><tree><noCountry><name sortKey="Koller, William C" sort="Koller, William C" uniqKey="Koller W" first="William C." last="Koller">William C. Koller</name></noCountry></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002010 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002010 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:DAA9FBEF109DE88D77954D1FD46657BF3F56D338
|texte= Neuroprotective Therapy for Parkinson's Disease
}}
| This area was generated with Dilib version V0.6.23. |  |